Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Douglas A. Treco was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard equity compensation.

Summary

• Director Douglas A. Treco received a grant of 13,000 stock options for CRISPR Therapeutics AG common shares.
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are set to expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of CRISPR Therapeutics stock.
• Vesting is subject to continued service to the company or its subsidiaries.

Future Outlook

The options vest in 12 equal monthly installments starting June 30, 2026, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term strategic objectives.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for mid-to-large cap biotech firms.
• The one-year vesting schedule is relatively aggressive compared to multi-year vesting schedules often seen in other industries.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Stock Options, Director Compensation